Veteran life-sciences investor and operating executive focused on commercialization and value-creation across biotech and medtech companies. Elizabeth Urish combines venture investing, corporate development and board experience to accelerate clinical-stage assets into strategic partnerships and exits. Background bridges scientific training and capital markets, with experience structuring licensing deals, syndicating rounds and advising management teams on go-to-market strategy. Regularly works with crossover investors and pharma corporates to de-risk programs and optimize capital allocation.
Veteran life-sciences investor and operating executive focused on commercialization and value-creation across biotech and medtech companies. Elizabeth Urish combines venture investing, corporate development and board experience to accelerate clinical-stage assets into strategic partnerships and exits. Background bridges scientific training and capital markets, with experience structuring licensing deals, syndicating rounds and advising management teams on go-to-market strategy. Regularly works with crossover investors and pharma corporates to de-risk programs and optimize capital allocation.
Focuses on late‑stage life‑sciences investments that bridge scientific validation and commercial exit, prioritizing clinical-stage biotech and medtech opportunities with clear de‑risking catalysts. Combines active board-level operational guidance with disciplined capital allocation, structuring licensing, syndication and pharma partnership pathways to shorten time horizon to strategic outcomes. Emphasizes clinical readouts, regulatory milestones and commercial fit as primary value drivers, maintains tight downside protection through staged financing, covenants and partner optioning while seeking asymmetric return profiles.
Focuses on late‑stage life‑sciences investments that bridge scientific validation and commercial exit, prioritizing clinical-stage biotech and medtech opportunities with clear de‑risking catalysts. Combines active board-level operational guidance with disciplined capital allocation, structuring licensing, syndication and pharma partnership pathways to shorten time horizon to strategic outcomes. Emphasizes clinical readouts, regulatory milestones and commercial fit as primary value drivers, maintains tight downside protection through staged financing, covenants and partner optioning while seeking asymmetric return profiles.
| Trades 639 | Longs Won 479/639 74% | Profit Factor 20.56 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $316,873.7 |
| Average Win $111,957.58 | Best Trade (Aug 14) $3.79M | Sharpe Ratio -11.45 |
| Average Loss -$16,300.38 | Worst Trade (Dec 31) -$300,824.18 | Z-Score 12.62 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 2w 1d | Expectancy $79,842.91 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 10,204 | 9,184 | 8,163 | 7,143 | 6,122 | 5,102 | 4,082 | 3,061 | 2,041 | 1,020 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 21,972 | $4.88M | $6.88M | - | $2.01M | 41.2% | +0.285% |
ABBV AbbVie Inc. | 3,294 | $589,924.33 | $809,961.66 | - | $220,037.33 | 37.3% | +0.828% |
ADI Analog Devices, Inc. | 875 | $209,378.64 | $341,083.75 | - | $131,705.11 | 62.9% | +3.313% |
AMAT Applied Materials, Inc. | 1,590 | $291,082 | $857,486.98 | - | $566,404.98 | 194.59% | +2.241% |
AMD Advanced Micro Devices, Inc. | 2,700 | $428,186.56 | $1.31M | - | $877,209.47 | 204.87% | -1.185% |
AMGN Amgen Inc. | 644 | $210,787.64 | $264,671.13 | - | $53,883.49 | 25.56% | +1.514% |
AMZN Amazon.com Inc | 13,447 | $2.49M | $3.69M | - | $1.2M | 48.37% | +0.801% |
APH Amphenol Corporation | 3,266 | $205,104.8 | $276,254.61 | - | $71,149.81 | 34.69% | -0.844% |
AVGO Broadcom Inc. | 4,121 | $820,131.07 | $1.76M | - | $941,699.41 | 114.82% | +1.654% |
AXP American Express Company | 871 | $254,540.58 | $297,011 | - | $42,470.42 | 16.69% | -0.467% |
BAC Bank of America Corporation | 5,578 | $242,721.52 | $352,306.48 | - | $109,584.96 | 45.15% | +0.254% |
BLK BlackRock, Inc. | 238 | $240,595.77 | $270,463.2 | - | $29,867.43 | 12.41% | +0.629% |
BNY BlackRock New York Municipal Income Trust | 2,022 | $239,869.86 | $318,646.98 | - | $78,777.12 | 32.84% | -0.774% |
BRK-B Berkshire Hathaway Inc. | 1,563 | $753,025.31 | $815,573.4 | - | $62,548.09 | 8.31% | -0.536% |
CAT Caterpillar Inc. | 708 | $253,209.23 | $596,298.83 | - | $343,089.6 | 135.5% | -1.719% |
CB Chubb Limited | 576 | $203,063 | $201,778.56 | - | -$1,284.44 | -0.63% | -1.051% |
COR Cencora, Inc. | 697 | $169,857.84 | $223,374.57 | - | $53,516.73 | 31.51% | -1.394% |
COST Costco Wholesale Corporation | 1,340 | $970,910.04 | $1.27M | - | $299,128.53 | 30.81% | -0.143% |
CSCO Cisco Systems, Inc. | 5,853 | $358,813.62 | $710,671.26 | - | $351,857.64 | 98.06% | +0.447% |
CVS CVS Health Corporation | 2,452 | $176,484.84 | $234,607.36 | - | $58,122.52 | 32.93% | -0.561% |